Faculty Collaboration Database

Unrelated donor bone marrow transplantation for chronic myelogenous leukemia: a decision analysis. Ann Intern Med 1997 Dec 15;127(12):1080-8

Date

12/31/1997

Pubmed ID

9412310

DOI

10.7326/0003-4819-127-12-199712150-00005

Scopus ID

2-s2.0-14444276989 (requires institutional sign-in at Scopus site)   64 Citations

Abstract

BACKGROUND: Chronic myelogenous leukemia (CML) is an indolent but ultimately fatal disease. Because the natural history of CML varies and quality of life with CML may be excellent until shortly before death, deciding whether and when to pursue unrelated donor bone marrow transplantation is often difficult.

OBJECTIVE: To compare early transplantation, delayed transplantation, and no transplantation for patients with chronic-phase CML on the basis of discounted, quality-adjusted life expectancy.

DESIGN: A markov model comparing different strategies was constructed. This model considers patient age, quality of life, risk aversion, and the competing risks for CML progression and transplant toxicity.

SETTING: Therapeutic decision at the time of diagnosis of CML.

PATIENTS: The base case is a 35-year-old patient with intermediate-prognosis CML. Younger and older patients with better and worse prognoses are also evaluated.

INTERVENTION: Early transplantation, delayed transplantation, and no transplantation.

MEASUREMENTS: Quality-adjusted, discounted life expectancy.

RESULTS: For patients with newly diagnosed CML, transplantation within the first year provides the greatest quality-adjusted expected survival, although this benefit decreases with increasing patient age. For a 35-year-old patient with intermediate-prognosis CML, transplantation within the first year results in 53 more discounted, quality-adjusted years of life expectancy than does no transplantation. This finding is robust even with varying baseline assumptions.

CONCLUSIONS: These results support the use of early unrelated donor bone marrow transplantation for most patients with CML.

Author List

Lee SJ, Kuntz KM, Horowitz MM, McGlave PB, Goldman JM, Sobocinski KA, Hegland J, Kollman C, Parsons SK, Weinstein MC, Weeks JC, Antin JH

Author

Mary M. Horowitz MD, MS Professor in the Medicine department at Medical College of Wisconsin

MESH terms used to index this publication - Major topics in bold

Age Factors
Antineoplastic Agents
Bone Marrow Transplantation
Decision Support Techniques
Disease Progression
Humans
Interferon-alpha
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Male
Markov Chains
Middle Aged
Prognosis
Quality-Adjusted Life Years
Sensitivity and Specificity
Time Factors
Tissue Donors
Transplantation, Homologous